Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Propafenone: a new antiarrhythmic agent.

M S Chow1, C Lebsack, D Hilleman

  • 1Department of Pharmacy Services, Hartford Hospital, CT 06115.

Clinical Pharmacy
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colorimetric tetra-combo loop-mediated isothermal amplification assay for efficient SARS-CoV-2 detection.

Tropical biomedicine·2026
Same author

Hematologic and chemical changes observed during and after cardiac arrest in a canine model--a pilot study.

Pharmacotherapy·2001
Same author

Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects.

International journal of pharmaceutics·2001
Same author

An evaluation of the impact of gender and age on QT dispersion in healthy subjects.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2001
Same author

Effects of diaspirin cross-linked hemoglobin (DCLHb) during and post-CPR in swine.

The Journal of pharmacology and experimental therapeutics·2001
Same author

A placebo controlled evaluation of the antifibrillatory effects of carvedilol.

Journal of electrocardiology·2001
Same journal

Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

Clinical pharmacy·1993
Same journal

Accuracy of unbound-quinidine concentration determination after ultrafiltration.

Clinical pharmacy·1993
Same journal

Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

Clinical pharmacy·1993
Same journal

Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

Clinical pharmacy·1993
Same journal

Efficacy of nutritional supplements used by athletes.

Clinical pharmacy·1993
Same journal

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

Clinical pharmacy·1993
See all related articles

Propafenone, a class IC antiarrhythmic, effectively treats ventricular tachycardia and premature ventricular complexes but has variable bioavailability and drug interactions. Careful dosing is needed due to potential adverse effects, including proarrhythmia.

Area of Science:

  • Pharmacology
  • Clinical Therapeutics
  • Drug Metabolism

Background:

  • Propafenone is a Class IC antiarrhythmic agent with structural similarities to beta-blockers, possessing weak beta-blocking and calcium-channel-blocking activities.
  • Its pharmacokinetic profile exhibits significant inter-individual variability, particularly concerning bioavailability and elimination half-life, influenced by metabolic status (extensive vs. poor metabolizers) and food intake.

Purpose of the Study:

  • To review the chemical and pharmacologic properties of propafenone.
  • To examine its pharmacokinetics, drug interactions, clinical efficacy, adverse effects, and dosage recommendations.

Main Methods:

  • Literature review of propafenone's properties, efficacy, and safety.
  • Analysis of pharmacokinetic data, including absorption, bioavailability, metabolism, and elimination.

Related Experiment Videos

  • Compilation of reported drug interactions and adverse event profiles.

    • Main Results:

    • Propafenone demonstrates good oral absorption, but systemic bioavailability is low (12% at 300 mg) and influenced by dose, food, and metabolic status.
    • Elimination half-life varies significantly between extensive (5.5 hours) and poor metabolizers (17.2 hours).
    • Effective in treating ventricular tachycardia and suppressing premature ventricular complexes (PVCs), but less so for refractory cases. Drug interactions increase serum concentrations of digoxin, warfarin, metoprolol, and propafenone itself (with cimetidine).
    • Adverse effects occur in 21-32% of patients, with 3-7% experiencing serious events like proarrhythmia. Common side effects include dizziness, metallic taste, and nausea.

    Conclusions:

    • Propafenone is an effective antiarrhythmic, but its clinical utility is moderated by significant pharmacokinetic variability and potential for drug interactions.
    • Plasma concentration monitoring has limited predictive value for efficacy or electrophysiologic effects due to considerable inter-individual variation.
    • Adverse events, including serious proarrhythmic effects, necessitate careful patient selection and monitoring during propafenone therapy.